Dr. Koh founded Genome Opinion and leads R&D initiatives for drug development pipelines and collaboration with leading research institutes and pharmaceutical companies. Dr. Koh is currently Professor of Hematology / Medical Oncology at Seoul National University Hospital (“SNUH”), Korea.


  • PhD., Molecular and Clinical Oncology, Seoul National University, Korea
  • Medical Doctor, Seoul National University College of Medicine, Korea


  • 30+ publications (Blood Cancer Journal, Hematologica, Nature Communications, etc.)

CLINICAL TRIAL EXPERIENCE: Conducted 40+ clinical trials

  • An open–label, multicenter, phase1 trial valuating the safety and pharmacokinetics of escalating doses of BTCT4465A in patients with relapsed or refractory B-cell Non-Hodgkin’s lymphoma
  • A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)
  • A Modular Phase I/II, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD0466 Monotherapy or in Combination in Patients with Advanced Haematological Malignancies
  • A Phase I/II, Open-Label, Multicentre Study to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD4205 in Patients with Peripheral T Cell Lymphoma (PTCL)

Youngil Koh, MD / PHD

Co-Founder, Chief Executive Officer